So as to think about the clinicopathological qualities and endurance results of patients with ovarian clear cell carcinoma (CCC) to other epithelial disease types, a sum of 27,290 patients were broke down, incorporating 2,424 patients with CCC (8.9%), 3,505 patients with endometrioid malignant growth (EC) (12.8%), 2,379 patients with mucinous malignancy (MC) (8.7%) and 18,982 patients with serous disease (SC) (69.6%). Patients with EC had the most ideal visualization and patients with SC had the least fortunate forecast among all epithelial ovarian malignancies. Among patients with stage I disease, patients with CCC had a progressively ideal visualization contrasted and patients with SC, particularly following 60 months (milestone investigation results, HR=2.079, P=0.001) and had a more unfortunate anticipation contrasted and patients with MC [restricted mean endurance time (RMST) distinction, -3.434 months]. Among patients at stages III and IV, patients with CCC had a more unfortunate anticipation contrasted and patients with SC (RMST distinction in stage III, -7.588 months; RMST distinction in stage IV, -15.445 months) and had a progressively good forecast contrasted and patients with MC (RMST contrast in stage III, 10.850 months; RMST contrast in stage IV, 8.430 months). The current outcomes recommended that most patients with CCC displayed, high evaluation, a beginning period, one-sided status and were of a youthful age. All in all, patients with SC introduced the least fortunate visualization among all patients with epithelial ovarian malignancy and no noteworthy endurance contrast was found between patients with CCC and MC. In any case, subsequent to altering for stage utilizing pairwise examinations, the forecast of patients with CCC was seen as progressively positive contrasted and the patients with SC and more awful contrasted and patients with MC at stage I; the outcomes at stage III-IV were inverse and the guess of patients with CCC was more regrettable contrasted and the patients with SC and increasingly good contrasted and the patients with MC.

Presentation: Ovarian Clear cell carcinoma (OCCC) speaks to 5-10% of all essential ovarian carcinoma and the middle rate is 23% of all ovarian carcinoma at Rebagliati Hospital, in Peru. It is higher than those announced around the world.

Strategies: Medical records of patients with OCCC were reflectively looked into somewhere in the range of 2013 and 2016. Graphic classifications of the clinical and neurotic qualities of patients. DFS bends were checked on by the Kaplan-Meier strategy. The examinations as indicated by the clinical qualities were evaluated by the Logrank or Breslow test.

Results: 33 patients were incorporated. The middle follow-up was 1.4 years (0.9-1.9 y). 75.8% were more established than 45 years, 72.7% experienced ideal medical procedure. 46.4% had case break, 9.4% detailed lymphovascular tumor emboly, 34.2% putrefaction, 60.6% endometriosis and 51.5% peritumoral lymphocytes. 75% of cases introduced lingering malady under 1 cm. 60.6% had FIGO I, 9.1% II, 18.2% III and 12.1% IV. 58.5% got adjuvancy with Carboplatin/Paclitaxel and 75% of them finished the 6 courses. Repeat in patients who got adjuvant chemotherapy was 18.2% and the most successive site was at the peritoneal level (57.1%). The pace of DFS at one year was 78.8%. In the univariate investigation, patients with an age <45 years (p <0.001) and a FIGO III-IV clinical stage (p = 0.042) brought about lower illness free endurance.

Ends: Patients with age <45 years and FIGO III-IV could be indicator of poor DFS in OCCC.